Form 8-K ALNYLAM PHARMACEUTICALS, For: Feb 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Alnylam Pharmaceuticals (ALNY) PT Lowered to $142 at Piper Jaffray
February 8, 2019 8:51 AM ESTPiper Jaffray analyst Edward Tenthoff lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $142.00 (from $152.00) while maintaining a Overweight rating.
... More


